The study of elite controllers: A pure academic exercise or a potential pathway to an HIV-1 vaccine?

Current Opinion in HIV and AIDS

Volumn 6, Issue 3, 2011, Pages 147-150

  Blankson, Joel N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INTESTINE LYMPHATIC TISSUE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

AIDS VACCINES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS;

EID: 79955476669     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283457868     Document Type: Editorial

References (42)

1. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-991.
2. Rhodes DI, Ashton L, Solomon A, et al. Characterization of three net-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression Australian Long-Term Nonprogressor Study Group. J Virol 2000; 74: 10581-10588.
3. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007; 81: 2508-2518.
4. Lamine A, Caumont-Sarcos A, Chaix ML, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007; 21: 1043-1045. (Pubitemid 46684337)
5. + T cells in HIV elite controllers. Clin Infect Dis 2010; 51: 233-238.
6. Miura T, Brockman MA, Schneidewind A, et al. HLA-B57/b*5801 human immunodeficiency type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte (corrected) recognition. J Virol 2009; 83: 2743-2755.
7. Lassen KG, Lobritz MA, Bailey JR, et al. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog 2009; 5:e1 000377.
8. + elite suppressors despite CTL escape mutations. J Exp Med 2006; 203: 1357-1369.
9. Bailey JR, Lassen KG, Yang HC, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006; 80: 4758-4770.
10. Leslie AJ, Rafferott KJ, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10: 282-289.
11. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617-3623.
12. Bailey JR, O'Connell K, Yang HC, et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol 2008; 82: 7395-7410.
13. O'Connell KA, Brennan TP, Bailey JR, et al. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 2010; 84: 7018-7028.
14. Mens H, Kearney M, Wiegand A, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010; 84: 12971-12981.
15. Salgado M, Brennan TP, O'Connell KA, et al. Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. Retrovirology 2010; 7: 94.
16. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97: 2709-2714. (Pubitemid 30159236)
17. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330: 1551-1557.
18. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3: 1061-1068.
19. + T cells. Blood 2006; 107: 4781-4789.
20. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104: 6776-6781.
21. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29: 1009-1021.
22. Ferre AL, Hunt PW, Critchfield JW, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009; 113: 3978-3989.
23. Saez-Cirion A, Sinet M, Shin SY, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009; 182: 7828-7837.
24. Hersperger AR, Pereyra F, Nason M, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010; 6:e1000917.
25. Loffredo JT, Sidney J, Bean AT, et al. Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-BOS and HLA-B*2705, bind peptides with sequence similarity. J Immunol 2009; 182: 7763-7775.
26. Valentine LE, Loffredo JT, Bean AT, et al. Infection with 'escaped' virus variants impairs control of simian immunodeficiency virus SIVmac239 replication in Mamu-B*08-positive macaques. J Virol 2009; 83: 11514-11527.
27. + T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007; 81: 3465-3476.
28. Emu B, Sinclair E, Hatano H, et al. HLA class l-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008; 82: 5398-5407. (Pubitemid 351705247)
29. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197: 563-571. (Pubitemid 351321534)
30. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31: 429-434. (Pubitemid 35154456)
31. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39: 733-740. (Pubitemid 46848586)
32. Goujard C, Chaix ML, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is 'HIV controller' status established? Clin Infect Dis 2009; 49: 982-986.
33. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009; 200: 1714-1723.
34. Bailey JR, Zhang H, Wegweiser BW, et al. Evolution of HIV-1 in an HLA-B*57positive patient during virologie escape. J Infect Dis 2007; 196: 50-55. (Pubitemid 46982737)
35. Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13: 1032-1034. (Pubitemid 47517505)
36. Doria-Rose NA, Klein RM, Manion MM, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009; 83: 188-199.
37. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23: 897-906.
38. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458: 636-640.
39. Sajadi MM, Guan Y, Devico AL, et al. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 2011. [Epub ahead of print]
40. McElrath MJ, De Rosa SC, MoodieZ, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372: 1894-1905.
41. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
42. Migueles SA, Rood JE, Berkley AM, et al. Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog (in press).